Eliem Therapeutics (ELYM) Stock Price, News & Analysis

Company Overview

Eliem Therapeutics, Inc. is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.

The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury. Preclinical studies have demonstrated promising effects on motor function and sensory processing, and Eliem is preparing for initial clinical development. In addition to ELI-200, the company maintains a pipeline of next‐generation compounds aimed at a variety of CNS targets, with each asset benefiting from a robust preclinical safety and efficacy profile.

Headquartered in San Diego, California, Eliem Therapeutics was founded to translate cutting‐edge neuroscience research into practical therapies that improve patient outcomes. The company’s leadership team combines deep expertise in drug development, regulatory strategy and commercial planning. Eliem collaborates with academic institutions and contract research organizations to advance its programs, with a long-term goal of delivering first‐in‐class treatments to patients worldwide.

Key Stats

• Today's Range: $2.37 to $2.42
• 50-Day Range: $1.28 to $2.48
• 52-Week Range: $2.35 to $11.55
• Volume: 230,134 shs
• Average Volume: 486,688 shs
• Market Capitalization: $71.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELYM Stock Analysis - Frequently Asked Questions

How have ELYM shares performed this year?

Eliem Therapeutics' stock was trading at $1.80 on January 1st, 2025. Since then, ELYM shares have increased by 33.3% and is now trading at $2.40.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?

Eliem Therapeutics (ELYM) raised $75 million in an initial public offering (IPO) on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eliem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELYM
• CIK: 1768446
• Web: www.eliemtx.com
• Phone: 877-354-3689
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.03%
• Return on Assets: -45.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 60.41
• Quick Ratio: 60.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.90 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 29,752,000
• Free Float: 28,354,000
• Market Cap: $71.40 million
• Optionable: Not Optionable
• Beta: -0.39